-$0.31 EPS Expected for Acorda Therapeutics Inc (NASDAQ:ACOR) This Quarter

Equities research analysts expect Acorda Therapeutics Inc (NASDAQ:ACOR) to report earnings per share of ($0.31) for the current fiscal quarter, Zacks Investment Research reports. Five analysts have made estimates for Acorda Therapeutics’ earnings. The highest EPS estimate is ($0.16) and the lowest is ($0.45). Acorda Therapeutics reported earnings of ($0.46) per share during the same quarter last year, which indicates a positive year over year growth rate of 32.6%. The business is scheduled to issue its next earnings report on Monday, November 2nd.

On average, analysts expect that Acorda Therapeutics will report full-year earnings of ($1.64) per share for the current financial year, with EPS estimates ranging from ($1.83) to ($1.45). For the next year, analysts anticipate that the business will report earnings of ($1.84) per share, with EPS estimates ranging from ($2.50) to ($1.00). Zacks’ EPS calculations are an average based on a survey of analysts that cover Acorda Therapeutics.

Acorda Therapeutics (NASDAQ:ACOR) last posted its quarterly earnings results on Tuesday, August 4th. The biopharmaceutical company reported ($0.37) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.64) by $0.27. Acorda Therapeutics had a negative net margin of 138.66% and a negative return on equity of 19.55%.

Several analysts have issued reports on the company. Zacks Investment Research raised Acorda Therapeutics from a “sell” rating to a “hold” rating in a research note on Monday, August 10th. Jefferies Financial Group reaffirmed a “hold” rating and issued a $1.00 target price on shares of Acorda Therapeutics in a research note on Tuesday, August 11th. One analyst has rated the stock with a sell rating, three have assigned a hold rating and two have assigned a buy rating to the company. Acorda Therapeutics currently has a consensus rating of “Hold” and a consensus target price of $4.35.

ACOR traded up $0.04 during midday trading on Wednesday, hitting $0.55. The stock had a trading volume of 1,533,653 shares, compared to its average volume of 2,135,289. The company has a market cap of $21.73 million, a P/E ratio of -0.12 and a beta of 1.46. The business has a fifty day moving average of $0.60 and a 200 day moving average of $0.83. The company has a debt-to-equity ratio of 0.54, a quick ratio of 0.90 and a current ratio of 1.14. Acorda Therapeutics has a 1 year low of $0.42 and a 1 year high of $3.75.

Institutional investors have recently added to or reduced their stakes in the stock. Royal Bank of Canada raised its stake in shares of Acorda Therapeutics by 571.7% in the first quarter. Royal Bank of Canada now owns 32,826 shares of the biopharmaceutical company’s stock worth $30,000 after buying an additional 27,939 shares during the period. JPMorgan Chase & Co. grew its holdings in Acorda Therapeutics by 153.4% during the 1st quarter. JPMorgan Chase & Co. now owns 539,339 shares of the biopharmaceutical company’s stock valued at $502,000 after buying an additional 326,530 shares in the last quarter. Blair William & Co. IL purchased a new position in Acorda Therapeutics during the 2nd quarter valued at approximately $39,000. GSA Capital Partners LLP purchased a new position in Acorda Therapeutics during the 1st quarter valued at approximately $233,000. Finally, State Street Corp grew its holdings in Acorda Therapeutics by 1.6% during the 1st quarter. State Street Corp now owns 1,492,994 shares of the biopharmaceutical company’s stock valued at $1,392,000 after buying an additional 23,906 shares in the last quarter. 50.14% of the stock is currently owned by institutional investors.

Acorda Therapeutics Company Profile

Acorda Therapeutics, Inc, a biopharmaceutical company, develops and commercializes therapies for neurological disorders in the United States. The company markets Ampyra (dalfampridine), an oral drug to improve walking in patients with multiple sclerosis (MS); and Selincro, an orally administered drug for the treatment of alcohol dependence in Europe.

Recommended Story: Penny Stocks

Get a free copy of the Zacks research report on Acorda Therapeutics (ACOR)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Earnings History and Estimates for Acorda Therapeutics (NASDAQ:ACOR)

Receive News & Ratings for Acorda Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Acorda Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.